Claims

1. A compound, or a pharmaceutically acceptable salt thereof, selected from:

	
	
	
	
	

	
	
	
	
	
	

	
	
	
	
	

	
	
	
	
	
	

	
	
	
	
	
	

	
	
	
	
	

	
	
	
	

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is present in at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess.

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is present in at least 90% diastereomeric excess, at least 95% diastereomeric excess, or at least 99% diastereomeric excess.

4. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof for use in therapy.

6. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder mediated by complement activation or activation of the complement alternative pathway.

7. The use of claim 6, wherein the disease or disorder is selected from age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, intermediate uveitis, birdshot retino-chorioditis, sympathetic ophthalmia, ocular dicatricial pemphigoid, ocular pemphigus, nonartertic ischemic optic neuropathy, post-operative inflammation, retinal vein occlusion, glaucoma, Doyne honeycomb retinal dystrophy/Malattia leventinese, Sorsby fundus dystrophy, Late onset retinal macular dystrophy, North carolina macular dystrophy, Stargardt disease, corneal inflammatory diseases, neurological disorders such as multiple sclerosis, stroke, Guillain Barré Syndrome, spinal cord injury, traumatic brain injury, Parkinson's disease, Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis (ALS), Huntington's disease, multifocal motor neuropathy, autism spectrum disorders, schizophrenia , drug-induced neurotoxicity; disorders of inappropriate or undesirable complement activation such as hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, paroxysmal nocturnal hemoglobinuria, C3 glomerulonephritis (including dense deposit disease and C3 glomerulonephritis), IgA nephropathy, membranous nephropathy, including idiopathic membranous nephropathy, diabetic nephropathy, atypical hemolytic uremic syndrome, Hemolytic uremic syndrome, STEC-HUS (Shiga toxin–producing Escherichia coli hemolytic uremic syndrome), peridontitis, CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, protein-losing enteropathy (CHAPLE syndrome), inflammation or autoimmune diseases such as Crohn's disease, adult respiratory distress syndrome, myocarditis, post-ischemic reperfusion conditions, myocardial infarction, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis , renal ischemia, acute kidney injury, mesenteric artery reperfusion after aortic reconstruction, infectious disease or sepsis; COVID-19, immune complex disorders and autoimmune diseases, rheumatoid arthritis, osteoarthritis, Spondyloarthropathies including psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, SLE nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, tissue regeneration, neural regeneration, dyspnea, hemoptysis, acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia,

fibrogenic dust diseases, pulmonary fibrosis, asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis including anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides, other vasculitides, including Henoch-Schönlein vasculitis, Buerger's vasculitis, cryoglobulinemia, Kawasaki disease, Takayasu arteritis, immune complex-associated inflammation, antiphospholipid syndrome, glomerulonephritis and obesity; immune thrombocytopenia, Cold agglutinin disease, Warm autoimmune hemolytic anemia (wAIHA), thrombotic thrombocytopenic purpura (TTP), abdominal aortic aneurisms, and Grave's disease.

8. A pharmaceutical combination comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agent(s).